| Abstrakt: |
A recent study conducted at Duke University in Durham, North Carolina, has introduced a new technology called DART.2 (drug acutely restricted by tethering) that aims to manipulate specific cellular interactions within complex tissues. This second-generation cell-specific pharmacology technology offers optimized cellular specificity, allowing for the targeted delivery of drugs without off-target effects. The study showcases the versatility of DART.2 across multiple mouse-brain regions and describes its ability to manipulate native receptors on genetically defined neurons. The research concludes that DART.2 reagents provide higher cellular specificity for manipulating GABAA and AMPA receptors compared to previous methods. [Extracted from the article] |
